PMID- 26060825
OWN - NLM
STAT- MEDLINE
DCOM- 20160203
LR  - 20190723
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2015
DP  - 2015
TI  - Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin 
      Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly 
      Controlled on High-Dose Insulin: A Pilot Study.
PG  - 834903
LID - 10.1155/2015/834903 [doi]
LID - 834903
AB  - BACKGROUND: The concurrent use of a postprandial insulin sensitizing agent, such 
      as bromocriptine-QR, a quick release formulation of bromocriptine, a dopamine D2 
      receptor agonist, may offer a strategy to improve glycemic control and 
      limit/reduce insulin requirement in type 2 diabetes (T2DM) patients on high-dose 
      insulin. This open label pilot study evaluated this potential utility of 
      bromocriptine-QR. METHODS: Ten T2DM subjects on metformin (1-2 gm/day) and 
      high-dose (TDID >/= 65 U/day) basal-bolus insulin were enrolled to receive once 
      daily (morning) bromocriptine-QR (1.6-4.8 mg/day) for 24 weeks. Subjects with at 
      least one postbaseline HbA1c measurement (N = 8) were analyzed for change from 
      baseline HbA(1c), TDID, and postprandial glucose area under the curve of a 
      four-hour mixed meal tolerance test (MMTT). RESULTS: Compared to the baseline, 
      average HbA1c decreased 1.76% (9.74 +/- 0.56 to 7.98 +/- 0.36, P = 0.01), average 
      TDID decreased 27% (199 +/- 33 to 147 +/- 31, P = 0.009), and MMTT AUC(60-240) 
      decreased 32% (P = 0.04) over the treatment period. The decline in HbA(1c) and 
      TDID was observed at 8 weeks and sustained over the remaining 16-week study 
      duration. CONCLUSION: In this study, bromocriptine-QR therapy improved glycemic 
      control and meal tolerance while reducing insulin requirement in T2DM subjects 
      poorly controlled on high-dose insulin therapy.
FAU - Roe, Erin D
AU  - Roe ED
AD  - University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
FAU - Chamarthi, Bindu
AU  - Chamarthi B
AD  - Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
FAU - Raskin, Philip
AU  - Raskin P
AD  - University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150428
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Blood Glucose)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 3A64E3G5ZO (Bromocriptine)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/*metabolism
MH  - Bromocriptine/administration & dosage/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Dopamine Agonists/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Insulin/administration & dosage/*therapeutic use
MH  - Male
MH  - Metformin/administration & dosage/therapeutic use
MH  - Middle Aged
MH  - Pilot Projects
MH  - Treatment Outcome
PMC - PMC4427808
EDAT- 2015/06/11 06:00
MHDA- 2016/02/04 06:00
PMCR- 2015/04/28
CRDT- 2015/06/11 06:00
PHST- 2015/01/30 00:00 [received]
PHST- 2015/03/28 00:00 [accepted]
PHST- 2015/06/11 06:00 [entrez]
PHST- 2015/06/11 06:00 [pubmed]
PHST- 2016/02/04 06:00 [medline]
PHST- 2015/04/28 00:00 [pmc-release]
AID - 10.1155/2015/834903 [doi]
PST - ppublish
SO  - J Diabetes Res. 2015;2015:834903. doi: 10.1155/2015/834903. Epub 2015 Apr 28.